To examine the immunomodulatory effects and mechanisms of stem cell-derived extracellular vesicles (SC-EVs) in systemic lupus erythematosus (SLE) and multiple sclerosis (MS), highlighting their potential as therapeutic agents and their significance in improving current treatment strategies.
Key Findings:
SLE and MS share overlapping clinical features and immunopathological mechanisms, including dysregulated immune responses and compromised blood-brain barrier integrity, which may complicate treatment.
Stem cell-derived extracellular vesicles (SC-EVs), particularly mesenchymal stem cell-derived extracellular vesicles (MSC-EVs), can modulate immune responses and promote tissue repair, suggesting a dual role in therapy.
MicroRNA-146a-5p and microRNA-21-5p play a synergistic role in reprogramming immune responses in both diseases, indicating potential targets for therapeutic intervention.
Interpretation:
The findings suggest that SC-EVs could serve as effective cell-free immunotherapeutic agents by targeting common pathogenic processes in SLE and MS, potentially improving treatment strategies and warranting further clinical exploration.
Limitations:
The review primarily discusses preclinical studies, which may not fully translate to clinical outcomes, and potential biases in the literature could affect the findings.
Further research is needed to clarify the specific mechanisms and therapeutic potential of SC-EVs in human subjects, particularly in diverse populations.
Conclusion:
SC-EVs, especially MSC-EVs, represent a promising avenue for therapeutic intervention in SLE and MS, addressing shared immune dysfunction and promoting tissue regeneration, with a strong need for clinical validation.
